Therapeutic Area: Oncology

Sex bias in MHC I-associated shaping of the adaptive immune system

Schneider-Hohendorf et al.
Papers
Proceedings of the National Academy of Sciences
February 2018
Authors and Affiliates
Tilman Schneider-Hohendorfa, Dennis Görlichb, Paula Savolac, Tiina Kelkkac, Satu Mustjokic, Catharina C. Grossa, Geoffrey C. Owensd, Luisa Klotza, Klaus Dornmaire, Heinz Wiendla, and Nicholas Schwaba aDepartment of Neurology, University of Muenster, 48149 Muenster, Germany; bInstitute of Biostatistics and Clinical Research, University of Muenster, 48149 Muenster, Germany; cHematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, 00029 Helsinki, Finland; dDepartment of Neurosurgery, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095; and eInstitute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, 80539 Munich, Germany

Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non–Small Cell Lung Cancer

Mark et al.
American Journal of Respiratory and Critical Care Medicine
Papers
February 2018
Authors and Affiliates
Nicholas M. Mark1,2, Julia Kargl2,3, Stephanie E. Busch2, Grace H. Y. Yang2, Heather E. Metz2, Huajia Zhang2, Jesse J. Hubbard2, Sudhakar N. J. Pipavath4, David K. Madtes1,2, and A. McGarry Houghton1,2,5 1Division of Pulmonary and Critical Care, and 4Department of Radiology, University of Washington, Seattle, Washington; 2Clinical Research Division and 5Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; and 3Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Giaconne et al.
Lancet Oncology
Papers
January 2018
Authors and Affiliates
Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire, Bhaskar Kallakury, Joeffrey J Chahine, Maria Manning, Robin Mogg, Wendy M Blumenschein, Ming T Tan, Deepa S Subramaniam, Stephen V Liu, Ian M Kaplan, Justine N McCutcheon Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA (Prof G Giaccone MD,C Kim MD, J Thompson MSN,C McGuire MSN,Prof B Kallakury MD,J J Chahine MS, M Manning MD, Prof M T Tan PhD,D S Subramaniam MD, S V Liu MD, J N McCutcheon BS); Merck and Co, Kenilworth, NJ, USA (R Mogg PhD, W M Blumenschein BA); and Adaptive Biotechnologies, Seattle, WA, USA(I M Kaplan PhD)

T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study

Kuhs et al.
Papers
PLOS ONE
January 2018
immuneAccess
Authors and Affiliates
Krystle A. Lang Kuhs1,2, Shih-Wen Lin1 , Xing Hua1, Mark Schiffman1, Robert D. Burk3, Ana Cecilia Rodriguez4, Rolando Herrero4,5, Christian C. Abnet1, Neal D. Freedman1, Ligia A. Pinto6, David Hamm7, Harlan Robins7,8, Allan Hildesheim1, Jianxin Shi1, Mahboobeh Safaeian1 1National Cancer Institute, NIH, Bethesda, Maryland, United States of America, 2Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, 3Albert Einstein College of Medicine, Bronx, New York, United States of America, 4Proyecto Epidemiólogico Guanacaste, Fundación INCIENSA, San José, Costa Rica, 5Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France, 6HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America, 7Adaptive Biotechnologies, Seattle, Washington, United States of America, 8Fred Hutchinson Cancer Research Cancer, Seattle, Washington, United States of America

Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues

Brunner et al.
Allergy
Papers
December 2017
Authors and Affiliates
P. M. Brunner1, R. O. Emerson2, C. Tipton2, S. Garcet1, S. Khattri3, I. Coats1, J. G. Krueger1, E. Guttman-Yassky1,3 1The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA, 2Adaptive Biotechnologies Corporation, Seattle, WA, USA, 3Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence

Bailey et al.
Nature Communications
Papers
December 2017
Authors and Affiliates
Stefanie R. Bailey1,2,3, Michelle H. Nelson1,2,3,7, Kinga Majchrzak1,2,3,8, Jacob S. Bowers1,2,3, Megan M. Wyatt1,2,3, Aubrey S. Smith1,2,3, Lillian R. Neal1,2,3, Keisuke Shirai4,9, Carmine Carpenito5,10, Carl H. June5, Michael J. Zilliox6 & Chrystal M. Paulos1,2,3 1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. 2Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA. 3Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC 29425, USA. 4Hematology/Oncology Division, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. 5Department of Pathology and Laboratory Medicine, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA. 6Department of Public Health Sciences, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA. 7Aptevo Therapeutics, Seattle, WA 98121, USA. 8Present address: Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, 02-787, Poland. 9Department of Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 02714, USA. 10Present address: Eli Lilly and Company, New York, NY 10016, USA.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Germano et al
Nature
Papers
December 2017
Authors and Affiliates
Giovanni Germano1,2, Simona Lamba1, Giuseppe Rospo1, Ludovic Barault1,2, Alessandro Magrì1,2, Federica Maione1, Mariangela Russo1,2, Giovanni Crisafulli1,2, Alice Bartolini1, Giulia Lerda1,2, Giulia Siravegna1,2, Benedetta Mussolin1, Roberta Frapolli3, Monica Montone1, Federica Morano4, Filippo de Braud4,5, Nabil Amirouchene-Angelozzi1,6, Silvia Marsoni1, Maurizio D’Incalci3, Armando Orlandi7, Enrico Giraudo1,8, Andrea Sartore-Bianchi9, Salvatore Siena5,9, Filippo Pietrantonio4, Federica Di Nicolantonio1,2 & Alberto Bardelli1,2 1Candiolo Cancer Institute – FPO, IRCCS, Candiolo 10060, Turin, Italy. 2University of Turin, Department of Oncology, Candiolo 10060, Turin, Italy. 3IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan 20156, Italy. 4Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy. 5Department of Oncology and Hemat-Oncology Università degli Studi di Milano, Milan 20122, Italy. 6FIRC Institute of Molecular Oncology (IFOM), Milan 20139, Italy. 7Policlinico Universitario A. Gemelli, Roma 00168, Italy. 8University of Torino, Department of Science and Drug Technology, Turin 10125, Italy. 9Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan 20142, Italy.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz et al.
Cell
Papers
November 2017
Authors and Affiliates
Nadeem Riaz,1,2,3 Jonathan J. Havel,1 Vladimir Makarov,1,3 Alexis Desrichard,1 Walter J. Urba,4 Jennifer S. Sims,1,3 F. Stephen Hodi,5 Salvador Martin-Algarra,6 Rajarsi Mandal,7 William H. Sharfman,8 Shailender Bhatia,9 Wen-Jen Hwu,10 Thomas F. Gajewski,11 Craig L. Slingluff, Jr.,12 Diego Chowell,1,3 Sviatoslav M. Kendall,1,3 Han Chang,13 Rachna Shah,1 Fengshen Kuo,3 Luc G.T. Morris,3,7 John-William Sidhom,14 Jonathan P. Schneck,14 Christine E. Horak,13 Nils Weinhold,2 and Timothy A. Chan1,2,3 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 2Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 3Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 4Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR 97213, USA 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 6Medical Oncology, Clinica Universidad de Navarra, Instituto de Investigacion Sanitaria de Navarra, 31008 Pamplona, Spain 7Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 8Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA 9Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98105, USA 10Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 11Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA 12Department of Surgery and University of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA 22908, USA 13Bristol-Myers Squibb, Princeton, NJ 08648, USA 14Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Balachandran et al.
Nature
Papers
November 2017
Authors and Affiliates
Vinod P. Balachandran1,2,3, Marta Łuksza4, Julia N. Zhao1,2,3, Vladimir Makarov5,6, John Alec Moral1,2,3, Romain Remark7, Brian Herbst2, Gokce Askan2,8, Umesh Bhanot8, Yasin Senbabaoglu9, Daniel K. Wells10, Charles Ian Ormsby Cary10, Olivera Grbovic-Huezo2, Marc Attiyeh1,2, Benjamin Medina1, Jennifer Zhang1, Jennifer Loo1, Joseph Saglimbeni2, Mohsen Abu-Akeel9, Roberta Zappasodi9, Nadeem Riaz6,11, Martin Smoragiewicz12, Z. Larkin Kelley13,14, Olca Basturk8, Mithat Gönen15, Arnold J. Levine4, Peter J. Allen1,2, Douglas T. Fearon13,14, Miriam Merad7, Sacha Gnjatic7, Christine A. Iacobuzio-Donahue2,5,8, Jedd D. Wolchok3,9,16,17,18, Ronald P. DeMatteo1,2, Timothy A. Chan3,5,6,11, Benjamin D. Greenbaum19, Taha Merghoub3,9,18 & Steven D. Leach1,2,5,20 1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 4The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey, USA. 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 7Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 8Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 9Swim Across America/Ludwig Collaborative Laboratory, New York, New York, USA. 10Parker Institute for Cancer Immunotherapy, San Francisco, California, USA. 11Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 12Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK. 13Cold Spring Harbor Laboratory, New York, New York, USA. 14Department of Microbiology and Immunology, Weill Cornell Medical School, New York, New York, USA. 15Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 16Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 17Weill Cornell Medical College, Cornell University, New York, New York, USA. 18Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 19Tisch Cancer Institute, Departments of Medicine, Hematology and Medical Oncology, Oncological Sciences, and Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 20Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire, USA

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Briere et al.
Cancer Immunology
Immunotherapy
November 2017
Authors and Affiliates
David Briere1, Niranjan Sudhakar1, David M. Woods2, Jill Hallin1, Lars D. Engstrom1, Ruth Aranda1, Harrah Chiang1, Andressa L. Sodré2, Peter Olson1, Jeffrey S. Weber2, James G. Christensen1 1Mirati Therapeutics, Inc., 9393 Towne Center Dr, Suite 200, San Diego, CA 92121, 2NYU Langone Medical Center, New York, NY 10016, USA